Is Septerna Inc (SEPN) a Buy, Sell, or Hold?
NASDAQ : SEPN
Septerna Inc
$31.56 USD
-$2.51 (-7.37%)
- Volume
- 414.07K
- Average Volume
- 422.39K
- Market Capitalization
- $1.42B
- P/E Ratio
- -38.96
- Dividend Yield
- 0.00%
- Price Target
- $45.00
- Year High
- $38.04
- Year Low
- $10.62
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.71
NUMBER OF INSIDERS BUYING (LAST 12 MONTHS)
30
NUMBER OF INSIDERS SELLING (LAST 12 MONTHS)
32
AMOUNT OF INSIDER SELLING (LAST 12 MONTHS)
$249.4K
SEPN Estimated and Actual Revenue by Quarter
Get MSFT Insider Trade Alerts
SEPN Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Long Daniel D. | officer: SVP, Drug Discovery | 2026-07-01 | M-Exempt | 2.76 | 2026-07-02 |
| Long Daniel D. | officer: SVP, Drug Discovery | 2026-07-01 | S-Sale | 34.0964 | 2026-07-02 |
| Long Daniel D. | officer: SVP, Drug Discovery | 2026-07-01 | S-Sale | 34.8141 | 2026-07-02 |
| Long Daniel D. | officer: SVP, Drug Discovery | 2026-07-01 | M-Exempt | 2.76 | 2026-07-02 |
| RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 2026-06-26 | A-Award | 37.34 | 2026-06-30 |
| Shaikhly Samira | officer: Chief People Officer | 2026-06-29 | M-Exempt | 6.81 | 2026-06-30 |
| Shaikhly Samira | officer: Chief People Officer | 2026-06-29 | M-Exempt | 6.81 | 2026-06-30 |
| Shaikhly Samira | officer: Chief People Officer | 2026-06-29 | S-Sale | 35.18 | 2026-06-30 |
| Bassan Abraham | director | 2026-06-26 | A-Award | 37.34 | 2026-06-30 |
| Sharp Shalini | director | 2026-06-26 | A-Award | 37.34 | 2026-06-30 |
| Coulie Bernard | director | 2026-06-26 | A-Award | 37.34 | 2026-06-30 |
| Tong Jeffrey K | director | 2026-06-26 | A-Award | 37.34 | 2026-06-30 |
| Gottesdiener Keith Michael | director | 2026-06-26 | A-Award | 37.34 | 2026-06-30 |
| Ezekowitz Alan | director | 2026-06-26 | A-Award | 37.34 | 2026-06-30 |
| Simson Jake | director | 2026-06-26 | A-Award | 37.34 | 2026-06-30 |
| Long Daniel D. | officer: SVP, Drug Discovery | 2026-06-22 | M-Exempt | 11.7 | 2026-06-24 |
| Long Daniel D. | officer: SVP, Drug Discovery | 2026-06-22 | M-Exempt | 2.76 | 2026-06-24 |
| Long Daniel D. | officer: SVP, Drug Discovery | 2026-06-22 | S-Sale | 35.1001 | 2026-06-24 |
| Long Daniel D. | officer: SVP, Drug Discovery | 2026-06-22 | S-Sale | 35.9687 | 2026-06-24 |
| Long Daniel D. | officer: SVP, Drug Discovery | 2026-06-22 | M-Exempt | 11.7 | 2026-06-24 |
| Long Daniel D. | officer: SVP, Drug Discovery | 2026-06-22 | M-Exempt | 2.76 | 2026-06-24 |
| Shaikhly Samira | officer: Chief People Officer | 2026-06-12 | M-Exempt | 11.7 | 2026-06-16 |
| Shaikhly Samira | officer: Chief People Officer | 2026-06-12 | M-Exempt | 11.7 | 2026-06-16 |
| Shaikhly Samira | officer: Chief People Officer | 2026-06-12 | S-Sale | 35.0759 | 2026-06-16 |
| Shaikhly Samira | officer: Chief People Officer | 2026-06-01 | M-Exempt | 1.55 | 2026-06-03 |
| Shaikhly Samira | officer: Chief People Officer | 2026-06-01 | M-Exempt | 2.76 | 2026-06-03 |
| Shaikhly Samira | officer: Chief People Officer | 2026-06-01 | M-Exempt | 2.76 | 2026-06-03 |
| Shaikhly Samira | officer: Chief People Officer | 2026-06-01 | M-Exempt | 1.55 | 2026-06-03 |
| Shaikhly Samira | officer: Chief People Officer | 2026-06-01 | S-Sale | 27.7831 | 2026-06-03 |
| Shaikhly Samira | officer: Chief People Officer | 2026-06-01 | M-Exempt | 2.76 | 2026-06-03 |
| Shaikhly Samira | officer: Chief People Officer | 2026-06-01 | S-Sale | 28.7928 | 2026-06-03 |
| Shaikhly Samira | officer: Chief People Officer | 2026-06-01 | M-Exempt | 2.76 | 2026-06-03 |
| Shaikhly Samira | officer: Chief People Officer | 2026-06-01 | S-Sale | 29.6629 | 2026-06-03 |
| Shaikhly Samira | officer: Chief People Officer | 2026-05-26 | M-Exempt | 6.81 | 2026-05-28 |
| Shaikhly Samira | officer: Chief People Officer | 2026-05-26 | M-Exempt | 6.81 | 2026-05-28 |
| Shaikhly Samira | officer: Chief People Officer | 2026-05-26 | S-Sale | 30.0607 | 2026-05-28 |
| Bhatt Elizabeth | officer: President and COO | 2026-04-15 | M-Exempt | 6.81 | 2026-04-17 |
| Bhatt Elizabeth | officer: President and COO | 2026-04-15 | S-Sale | 23.7558 | 2026-04-17 |
| Bhatt Elizabeth | officer: President and COO | 2026-04-15 | S-Sale | 25.2394 | 2026-04-17 |
| Bhatt Elizabeth | officer: President and COO | 2026-04-15 | S-Sale | 25.8623 | 2026-04-17 |
| Bhatt Elizabeth | officer: President and COO | 2026-04-15 | M-Exempt | 6.81 | 2026-04-17 |
| Shaikhly Samira | officer: Chief People Officer | 2026-03-02 | M-Exempt | 2.76 | 2026-03-04 |
| Shaikhly Samira | officer: Chief People Officer | 2026-03-02 | S-Sale | 27.5052 | 2026-03-04 |
| Shaikhly Samira | officer: Chief People Officer | 2026-03-02 | M-Exempt | 2.76 | 2026-03-04 |
| Shaikhly Samira | officer: Chief People Officer | 2026-03-02 | M-Exempt | 1.55 | 2026-03-04 |
| Shaikhly Samira | officer: Chief People Officer | 2026-03-02 | M-Exempt | 1.55 | 2026-03-04 |
| Shaikhly Samira | officer: Chief People Officer | 2026-03-02 | M-Exempt | 2.76 | 2026-03-04 |
| Shaikhly Samira | officer: Chief People Officer | 2026-03-02 | M-Exempt | 2.76 | 2026-03-04 |
| Shaikhly Samira | officer: Chief People Officer | 2026-03-02 | S-Sale | 28.1383 | 2026-03-04 |
| Bhatt Elizabeth | officer: President and COO | 2026-02-18 | M-Exempt | 6.81 | 2026-02-20 |
| Bhatt Elizabeth | officer: President and COO | 2026-02-18 | S-Sale | 28.4594 | 2026-02-20 |
| Bhatt Elizabeth | officer: President and COO | 2026-02-18 | S-Sale | 29.5831 | 2026-02-20 |
| Bhatt Elizabeth | officer: President and COO | 2026-02-18 | M-Exempt | 6.81 | 2026-02-20 |
| Long Daniel D. | officer: SVP, Drug Discovery | 2026-02-06 | A-Award | 25.41 | 2026-02-10 |
| Klein Uwe | officer: SVP, Biological Sciences | 2026-02-06 | A-Award | 25.41 | 2026-02-10 |
| Shaikhly Samira | officer: Chief People Officer | 2026-02-06 | A-Award | 25.41 | 2026-02-10 |
| Labrucherie Gil M | officer: Chief Financial Officer | 2026-02-06 | A-Award | 25.41 | 2026-02-10 |
| Kim Jae B. | officer: Chief Medical Officer | 2026-02-06 | A-Award | 25.41 | 2026-02-10 |
| Bhatt Elizabeth | officer: President and COO | 2026-02-06 | A-Award | 25.41 | 2026-02-10 |
| Finer Jeffrey | director, officer: Chief Executive Officer | 2026-02-06 | A-Award | 25.41 | 2026-02-10 |
| Wilson Mark Andrew | officer: Chief Legal Officer | 2026-02-06 | A-Award | 25.41 | 2026-02-10 |
| Wilson Mark Andrew | 2026-01-05 | 0 | 2026-01-15 | ||
| Long Daniel D. | officer: SVP, Drug Discovery | 2025-11-10 | S-Sale | 18.0586 | 2025-11-13 |
| Gottesdiener Keith Michael | director | 2025-09-25 | A-Award | 16.75 | 2025-09-29 |
| Gottesdiener Keith Michael | 2025-09-25 | 0 | 2025-09-29 | ||
| Klein Uwe | officer: SVP, Biological Sciences | 2025-08-18 | M-Exempt | 6.81 | 2025-08-19 |
| Klein Uwe | officer: SVP, Biological Sciences | 2025-08-18 | M-Exempt | 6.81 | 2025-08-19 |
| Klein Uwe | officer: SVP, Biological Sciences | 2025-08-18 | M-Exempt | 2.76 | 2025-08-19 |
| Klein Uwe | officer: SVP, Biological Sciences | 2025-08-18 | M-Exempt | 2.76 | 2025-08-19 |
| Klein Uwe | officer: SVP, Biological Sciences | 2025-08-18 | M-Exempt | 2.76 | 2025-08-19 |
| Klein Uwe | officer: SVP, Biological Sciences | 2025-08-18 | M-Exempt | 2.76 | 2025-08-19 |
| Shaikhly Samira | officer: Chief People Officer | 2025-08-07 | A-Award | 11.7 | 2025-08-11 |
| Bhatt Elizabeth | officer: President and COO | 2025-08-07 | A-Award | 11.7 | 2025-08-11 |
| Kim Jae B. | officer: Chief Medical Officer | 2025-08-07 | A-Award | 11.7 | 2025-08-11 |
| Labrucherie Gil M | officer: Chief Financial Officer | 2025-08-07 | A-Award | 11.7 | 2025-08-11 |
| Finer Jeffrey | director, officer: Chief Executive Officer | 2025-08-07 | A-Award | 11.7 | 2025-08-11 |
| Long Daniel D. | officer: SVP, Drug Discovery | 2025-08-07 | A-Award | 11.7 | 2025-08-11 |
| Klein Uwe | officer: SVP, Biological Sciences | 2025-08-07 | A-Award | 11.7 | 2025-08-11 |
| RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 2025-06-17 | A-Award | 10.24 | 2025-06-20 |
| Sharp Shalini | director | 2025-06-17 | A-Award | 10.24 | 2025-06-20 |
| Tong Jeffrey K | director | 2025-06-17 | A-Award | 10.24 | 2025-06-20 |
| Coulie Bernard | director | 2025-06-17 | A-Award | 10.24 | 2025-06-20 |
| Simson Jake | director | 2025-06-17 | A-Award | 10.24 | 2025-06-20 |
| Bassan Abraham | director | 2025-06-17 | A-Award | 10.24 | 2025-06-20 |
| Ezekowitz Alan | director | 2025-06-17 | A-Award | 10.24 | 2025-06-20 |
| Finer Jeffrey | director, officer: CEO and President | 2025-04-03 | M-Exempt | 2.76 | 2025-04-04 |
| Finer Jeffrey | director, officer: CEO and President | 2025-04-02 | M-Exempt | 2.76 | 2025-04-04 |
| Finer Jeffrey | director, officer: CEO and President | 2025-04-02 | M-Exempt | 2.76 | 2025-04-04 |
| Finer Jeffrey | director, officer: CEO and President | 2025-04-03 | M-Exempt | 2.76 | 2025-04-04 |